An Act to Protect Health Care for Rural and Underserved Areas by Prohibiting Discrimination by Participants in a Federal Drug Discount Program
LD 1018, titled the “Protect Health Care for Rural and Underserved Communities Act,” would create state protections for participants in the federal 340B drug discount program. The bill prohibits drug manufacturers and their agents from interfering with a 340B entity’s acquisition or delivery of 340B drugs to a contract pharmacy, and bars manufacturers from conditioning access on claims or utilization data unless required by federal authorities. It also restricts health insurance issuers, pharmacy benefits managers, and other third-party payors from imposing special terms, fees, clawbacks, network restrictions, audit burdens, billing modifiers, or other requirements that treat 340B entities differently from non-340B entities.
The bill further prohibits payors from reimbursing 340B entities at lower rates because a drug is a 340B drug, from charging patients extra because they choose a 340B provider, and from refusing to contract with or excluding a 340B entity for reasons tied to 340B participation. It expressly allows limited-distribution drugs required under federal law and states that the chapter does not apply to MaineCare as a payor for covered outpatient drugs. Violations would be enforceable under the Maine Unfair Trade Practices Act, and 340B entities could bring civil actions in Superior Court.
In practical terms, the bill would add a state-law enforcement layer protecting hospitals, clinics, pharmacies, and other covered providers that participate in the federal 340B program, especially those serving rural and underserved communities. It would limit the ability of manufacturers, PBMs, insurers, and other payors to use contract terms or reimbursement practices that could reduce the financial benefit of 340B participation. The bill also includes a federal preemption safeguard, stating it should not be applied in a way that conflicts with federal law.
The overall sentiment reflected in the bill title and sponsorship is supportive of preserving access to care in rural and underserved areas by defending the 340B program from discriminatory practices. No committee transcript or vote record was provided, so there is no documented floor or committee debate to indicate broader legislative sentiment beyond the bill’s stated purpose and bipartisan-looking sponsorship list.
The main point of contention likely centers on whether the bill goes too far in regulating private insurers, PBMs, and manufacturers, and whether its restrictions could conflict with federal 340B rules or existing contracting and reimbursement practices. Supporters would likely emphasize protecting safety-net providers and patient access, while opponents may argue it imposes new compliance burdens, limits payer flexibility, and could create litigation risk through UTPA enforcement and private lawsuits.
This bill would add a new chapter to Maine law protecting 340B entities from discriminatory practices by pharmaceutical manufacturers, health insurance issuers, pharmacy benefits managers, and other third-party payors. It would prohibit a range of conduct affecting acquisition, delivery, reimbursement, contracting, network participation, billing requirements, and patient charges related to 340B drugs, while excluding MaineCare as a payor and preserving compliance with federal law. It would also make violations actionable under the Maine Unfair Trade Practices Act and allow civil suits by affected 340B entities.
The bill appears generally favorable toward 340B providers and the communities they serve, with a clear policy goal of protecting rural and underserved health care access. The sponsorship pattern suggests support from multiple legislators, and the bill’s framing is strongly pro-provider and pro-access. No vote history or committee testimony was provided, so there is no recorded opposition or amendment activity to gauge the depth of support or resistance.
Likely areas of contention include the bill’s restrictions on manufacturers, insurers, and PBMs; whether its anti-discrimination rules interfere with existing reimbursement or network management practices; and whether the state provisions could be challenged as preempted by federal law. Supporters are likely 340B hospitals, clinics, pharmacies, and patient-access advocates, while opponents would likely be manufacturers, PBMs, insurers, and other payors concerned about operational burdens, pricing transparency requirements, and litigation exposure.